Alumnus on the Cutting Edge of
Biotechnology
and Medicine
For Immediate Release:
Jan. 22, 2008
David Stump '72 is executive vice president of Human Genome Sciences, Inc. and author/co-author of more than 90 publications.
RICHMOND, Ind. — Internationally
recognized as one of the earliest biotechnology researchers and
developers, David Stump '72 returns to speak at Earlham College
— the place where he first learned to put science in a global and
human context.
Stump, a physician and scientist who is executive
vice president of Human Genome Sciences Inc., presents "Engaging
Genes: At the Intersection of Biotechnology and Medicine" during
an Earlham convocation beginning at 1 p.m. Wednesday, Jan.
30, in Carpenter Hall's Goddard Auditorium. The event is free
and open to the public.
Stump has been associated with a number of innovative new therapies for
patients of heart attack, stroke, immunologic diseases and cancer.
"I have been very fortunate to be closely involved
in bringing important new biotechnology drugs to patients," Stump
says. "I
am especially proud to have played a key role in the studies
which demonstrated the lifesaving and life-improving potential
of clot dissolving therapy for patients suffering from heart
attack or stroke.
"Today my research and development team is
investigating a novel new genomic treatment for patients with systemic
lupus erythematosis, a disease affecting predominantly young women and
without an effective new therapy in the last 40 years."
Human Genome Sciences also is in the late stages of work on ABthrax,
a new antibody drug effective against anthrax infection, which is planned
to be made available to governments as a defense against bioterrorism.
It was announced in December that clinical trials showed that ABthrax
improved survival rates up to 64 percent in monkeys infected with anthrax.
"ABthrax is the result of cutting edge research but a drug which
I hope will never be used," he says.
During the convocation, Stump also will discuss the impact Earlham has
had on his career in gene identification and manipulation in medical and
scientific advances achieved through biotechnology.
"I credit my Earlham experience for much of the satisfaction I
have enjoyed during my professional career," Stump says. "It
was there that I gained the fundamental skills to learn science
as well as being challenged to always put science in a global and human
context. Earlham inspired me to see the potential for change as energizing
and worthy of exploration."
— EC —
Contact:
Mark Blackmon,
director of media relations
765/983-1256 — E-Mail
Mark

|